Item 1.01 Entry into a Material Definitive Agreement.
On September 15, 2021, Global Wholehealth Partners Corporation (the "Company")
entered into a Memorandum of Understanding ("MOU") with Avant Gen, Inc. and Pan
Probe Biotech to optimize a rapid Covid-19 antigen test currently being
developed by AvantGen, Inc. and NanoComposix and/or to develop dipstick-based
rapid Covid-19 test by AvantGen, Inc. and the Company. Pan Probe Biotech and the
Company working together have developed a very specialized COVID Test using
Antibodies which had been approved by National Institute of Health. With Pan
Probe Biotech's technology and the special Antibodies the New generation Test
for COVID is available.
The foregoing description of the MOU does not purport to be completed and is
qualified in its entirety by reference to the MOU, which is filed as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
About AvantGen
AvantGen, Inc is a leader in the use of yeast display technology for antibody
discovery and optimization. Founded by experts in the creation of antibody
discovery and optimization platforms, AvantGen excels in the rapid generation of
antibodies for therapeutic, diagnostic and research tool applications. The
Company's platforms include a robust yeast display system, large natural human
antibody database, fully human antibody libraries comprised of over 100 billion
antibody clones displayed by yeast cells, NK and T cell engager technology, flow
cytometry-based and other screening technologies, as well as novel methodologies
for rabbit monoclonal antibody generation. These versatile platforms can be used
to discover and optimize antibodies directed at specific disease targets,
affinity mature existing antibodies to improve their binding properties and
humanize antibodies to render non-human antibodies suitable for human
therapeutic applications, as well as generate rabbit monoclonal antibodies for
applications that need extremely high specificity, such as antibodies capable of
distinguishing point mutations and post-translational modifications for IHC, and
anti-idiotype antibodies for PK studies. AvantGen's partners include
pharmaceutical, biotech, diagnostic and government entities, many of which are
repeat customers.
2
About Pan Probe Biotech
Pan Probe Biotech is a manufacturer and supplier of quality, rapid diagnostic
test kits/medical devices. We offer a variety of products suitable for
point-of-care use in the clinical setting, for forensic diagnostics and for
research purposes. Our product lines focus specifically on rapid tests to detect
drugs of abuse, fertility, ovulation & pregnancy, with significant, additional
efforts in infectious disease & cancer detection. Our tumor marker rapid test
products include diagnostic kits for the detection of fecal occult bleeding
(FOB) and prostate specific antigen (PSA). The PSA tests include a
semi-quantitative test that provides a third band as an in-test quantitative
reference. The products exist for both blood serum and whole blood. The FOB test
uses prepared fecal samples but can also detect blood in urine. The tumor marker
diagnostic kits come with accessories and running buffers. Tests are designed to
be read within ten minutes.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Document Location
10.1 Memorandum of Understanding Global Wholehealth Filed Herewith
Partners Corporation, AvantGen, Inc. and Pan Probe
Biotech, dated September 15, 2021
© Edgar Online, source Glimpses
GLOBAL WHOLEHEALTH PARTNERS CORPORATION 
